Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
Joincare Pharmaceutical Group Industry Co., Ltd
177 participants
Nov 7, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single oral dose, administered according to a weight-tiered dosing scheme.
Oral suspension, administered twice daily for 5 days, matched to the weight-based dosing of active oseltamivir.
Oral suspension, administered twice daily for 5 days according to the approved weight-based dosing regimen.
Single oral dose, matched to the weight-tiered dosing scheme of active JKN2301.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07357051